Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is a promising company with a diversified portfolio of products in Phase 2 trials, including ALTO-207 which is expected to be the primary driver of share price appreciation. While there are third party and commercial risks involved, the company's promising early evidence in depressive disorders makes it an interesting investment opportunity with a strong cash position to support its endeavors. However, the recent ALTO-101 program's failure to meet primary endpoints and subsequent deprioritization may impact the company's valuation and future partnerships.

Bears say

Alto Neuroscience is a clinical-stage biopharmaceutical company with a risky outlook due to the high failure rates of clinical trials in depression and the unproven nature of its biomarker approach. The company also faces financial risks and third party risks, and its valuation is complex and reliant on forward assumptions. With the company needing to raise additional capital and its lead asset not expected to have top-line results until 2H27, there is potential for share dilution and uncertainty surrounding the success of its pipeline. Additionally, competition from established companies and potential competitors in the market could impact the company's success.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.